In just concluded Meeting of Board of Directors, the Board approved and considered the following items: 1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Board approved unaudited financial results for the quarter ended June 30, 2025. Standalone revenue from operations rose to ₹2,564 lacs from ₹2,133.4 lacs in Q1 FY25, a growth of about 20% YoY, and consolidated revenue grew to ₹3,417.75 lacs (up ~20.7% YoY). Despite the strong top-line, standalone net profit was nearly flat at ₹414.95 lacs (vs ₹416.60 lacs YoY) because raw material costs spiked sharply to ₹1,826.97 lacs from ₹1,118.87 lacs a year ago. Consolidated net profit rose modestly to ₹501.64 lacs from ₹465.84 lacs. Statutory auditor R Pugalia & Company issued an unmodified limited review report on both sets of results, and the company disclosed related-party transactions of ₹322.93 lacs in inter-company sales with its subsidiary Deccan Remedies Ltd.
The double-digit revenue growth signals healthy demand, but flat standalone earnings highlight margin pressure from rising input costs, making the outcome broadly neutral for shareholders. Watch whether raw material costs ease in coming quarters to revive profit growth.